Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (225)	9/28/2001 9:32:37 AM
From: aknahow	Read Replies (1) \| Respond to of 1022

Don't know why the XOMA patents would not apply to human cell expression. XOMA claims all phage companies will need to license the technology and this release about the recent license to Dompe mentions a fully human FAB. "XOMA Licenses Recombinant Pharmaceutical Production Technology to Dompe SpA Berkeley, CA -- September 18, 2001 -- XOMA Ltd. (NASDAQ: XOMA), today announced the granting to Dompé SpA, (Milan, Italy) of a non-exclusive license for the use of XOMA’s patented technology for biopharmaceutical production. Dompé is using the technology in developing a fully human Fab fragment for radioimmunotherapy of ovarian carcinoma. Production of antibody domains using XOMA’s bacterial cell expression system reduces production costs, increases product yields and improves process control in the manufacture of genetically engineered proteins. "Relapsing ovarian carcinoma still represents a significantly unmet medical need," said Sergio Dompé, the Italian company’s C.E.O. "In close collaboration with the Italian National Cancer Institute in Milan, Dompé is focusing on the research and development of a novel fully human Fab fragment targeting ovarian carcinoma cells. With the XOMA license, we now have access to an essential technology platform for the development of a fully human Fab for radio-immunotherapy of ovarian carcinoma." "We are pleased that Dompé has licensed our antibody expression technology to develop its Fab therapeutic," said Jack Castello, President, Chairman and CEO of XOMA. "Our patented technology is fundamental for the manufacture of antibody-based products in bacteria. With the recent increase in interest in antibody discovery and development, our proprietary technologies and development capabilities are more valuable than ever to biopharmaceutical companies developing novel recombinant therapeutics." About Antibody Expression in Bacteria Bacterial antibody expression is an enabling technology used to develop and manufacture, as well as discover and screen, recombinant antibody-based products. XOMA scientists were the first to demonstrate the secretion of antibody domains directly from bacterial cells as fully functional, properly folded molecules. The company has received nine U.S. patents to date relating to aspects of its bacterial cell expression system, including six patents that broadly cover the secretion of functional immunoglobulins from bacteria, including antibody fragments such as Fab and single-chain antibodies. Corresponding foreign patents have also been granted. Bacterial antibody expression is also a key technology used in multiple systems for high-throughput screening of antibody domains. Expression of antibodies by phage display technology, for example, depends upon the expression and secretion of antibody domains from bacteria as properly folded functional proteins. Therefore, access to XOMA’s patent estate is necessary for the practice of antibody phage display and other antibody screening applications. XOMA’s bacterial cell production system has been licensed to approximately 25 biopharmaceutical developers. They are applying the system to select and produce recombinant proteins, including therapeutic and diagnostic antibodies, vaccines, toxins, and enzymes, as well as recombinant expression vectors for research use."